Company Description
Acadia Pharmaceuticals, Inc.. The Group's principal activity is discovers, develops and commercialization of small molecule drugs for the treatment of central nervous system disorders. It currently has five programs in clinical development as well ...
Related Business Topics
Breaking News
ABC News - November 09, 2009 4:36 PM
Acadia Pharmaceuticals Inc. said Monday its third-quarter loss narrowed on lower costs and a boost in revenue from its drug development partners. The development-stage biopharmaceutical company lost $8.7 million, or 23 cents per share, compared with a ...
Reuters - September 01, 2009 1:52 PM
* Acadia co-developing the drug with Biovail * Acadia shares sink 68 pct; Biovail down 2 pct (Adds analyst comment, bylines; updates shares) NEW YORK, Sept 1 (Reuters) - Acadia Pharmaceuticals Inc (ACAD.O) said on Tuesday its experimental drug for ...
ABC News - September 01, 2009 11:40 AM
Shares of Acadia Pharmaceuticals Inc. plunged Tuesday after the company said its drug candidate pimavanserin failed to meet key treatment goals in a late-stage study focusing on patients with Parkinson's disease psychosis. The San Diego-based company's ...
Forbes.com - September 01, 2009 10:43 AM
NEW YORK, Sept 1 (Reuters) - Acadia Pharmaceuticals ( ACAD - news - people ) Inc said on Tuesday its experimental drug for psychosis related to Parkinson's disease failed to meet its primary goal in a late-stage trial, sending its shares down 68 percent. ...
Forbes.com - September 01, 2009 10:10 AM
TORONTO, Sept 1 (Reuters) - Biovail Corp: * Biovail Corp ( BVF - news - people ) CEO says there are other alternatives for Parkinsons disease drug despite disappointing phase 3 results * To discuss next steps for Pimavanserin with co-development partner ...
